medigraphic.com

2015, Number 3

<< Back Next >>

Rev Hematol Mex 2015; 16 (3)

Prognostic influence of CD20+ on survival free of relapse and on therapeutic results of adult patients with de novo acute lymphoblastic leukemia submitted to intensive chemotherapy

Alvarado-Ibarra M, Trejo-Gómora J, López-Hernández M, Álvarez-Vera JL, Ortiz-Zepeda SM

Language: Spanish
References: 27
Page: 189-197
PDF size: 500.24 Kb.


ABSTRACT

Background: The close relation among phenotypic subgroups of acute lymphoblastic leukemia in particular impacts, in part, on prognosis. A phenotypic subgroup corresponds to the expression of the molecule of surface CD20, which is a specific antigen of cells of B linage, expressed in normal and malignant cells during differentiation of cells B.
Objective: To know the prognostic value of the antigen CD20 on survival free of relapse and on therapeutic failure in adult subjects with lymphoblastic acute leukemia de novo receiving intensive chemotherapy.
Material and method: A retrolective and comparative study, done from January 2004 to January 2014, that analyzed adult patients with diagnosis of acute lymphoblastic leukemia receiving an intensive chemotherapy protocol LAL 6 or LAL 10, attended at Hematology Service of National Medical Center 20 de Noviembre, ISSSTE, Mexico City. Patients were divided according to the intensity of expression of CD20 and then were subdivided taking as parameter 30% of expression of CD20 for the analysis of the study; survival free of relapse, survival free of event and overall survival, as well as other factors of bad prognosis, were analyzed.
Results: When comparing patients with expression of CD20 higher than 30% vs expression lower tan 30%, we found in a follow-up of five years, survival free of relapse of 24 months vs 50 months (p 0.02), survival free of event of 10 vs 36 months (p 0.003) and overall survival of 39 vs 53 months (p 0.03). Expression of surface marker CD20 higher tan 30% impacts significantly on survival free of relapse (10 vs 30 months, p 0.037), survival free of event (9 months vs 30 months, p 0.018) and overall survival (10 months vs 50 months, p 0.037) in patients submitted to protocol LAL 10.
Conclusions: Survival free of relapse, free of event and overall was better in patients with expression of CD20 lower than 30% younger than 35 years old.


REFERENCES

  1. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396-4407.

  2. Thomas DA. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program 2007;2007:435-443.

  3. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999;26:79-87.

  4. Thomas DA, O’Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906-3911.

  5. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580.

  6. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007;8(suppl 2):S57-S62.

  7. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998;51:364- 369.

  8. Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088.

  9. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561-1570.

  10. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67:1270-1281.

  11. Borowitz MJ, Shuster J, Carroll AJ, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood 1997;89:3960-3966.

  12. Jeha S, Behm F, Pei D, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2006;108:3302-3304.

  13. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 1990;8:994-1004.

  14. Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547-561.

  15. Cortes J, O’Brien SM, Pierce S, Keating MJ, et al. The value of highdose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 995;86:2091-2097.

  16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1965;53:457-481.

  17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. J R Stat Soc 1966;50:163-170.

  18. Fleming TR, Harrington DP. Counting processes and survival analysis. New York: Wiley, 1991.

  19. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.

  20. Thomas DA, Kantarjian H, Faderl S, et al. Update of the modified hyper-CVAD regimen with or without rituximab as frontline therapy of adults with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (LL) [abstract]. Blood 2007;110:831a. Abstract 2824.

  21. Hoelzer D, Hiddemann W, Baumann A, et al. High survival rate in adult Burkitt’s lymphoma/leukemia and diffuse large B-cell lymphoma with mediastinal involvement [abstract]. Blood 2007;110:159a. Abstract 518.

  22. Santana VM, Crist WM, Rivera GK, Look AT, Behm FG, Raimondi SC, Pui CH. Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia. Leukemia 1990;4:87-90.

  23. Nachman JB. Adolescents with acute lymphoblastic leukemia: a new “age”. Rev Clin Exp Hematol 2003;7:261- 269.

  24. Nachman JB. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukemia. Br J Haematol 2005;130:166-173.

  25. Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwing WD, Riehm H, Scharappe M. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from trails ALL-BFM 86, 90 and 95. Klin Padiatr 2005;217:310-320.

  26. López Hernández MA, Alvarado Ibarra M, Jiménez Alvarado RM, De Diego Flores JE, González Avante CM. Adolescentes con leucemia aguda infoblástica de novo: eficacia y seguridad de un protocolo pediátrico versus uno de adultos. Gac Méd Méx 2008;144:485-489.

  27. Rachel W, Di Bernardo M, Richards, Rossi D, Crowther- Swanepoel D, Gaidano G, Oscier DG, Catovsky D, Houlston RS. Association between single nucleotide polymorphismgenotype and outcome of patients with chronic and acute lymphocytic leukemia in a randomized chemotherapy trial. Haematologica 2011;96:1496-1503.




2020     |     www.medigraphic.com